Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

Zora Vukobrat-Bijedic1, Azra Husic-Selimovic1, Lejla Mehinovic2, Amila Mehmedovic3, Dzelaludin Junuzovic4, Ivana Bjelogrlic5, Amelia Sofic6, Aleksandra Djurovic6

Gastroenterohepatology department, Clinical Center of Sarajevo, University Sarajevo, Bosnia and Herzegovina1
Pathology Department, Clinical Center of Sarajevo, University Sarajevo, Bosnia and Herzegovina 2
Urology department, Clinical center of Sarajevo University, Sarajevo, Bosnia and Herzegovina3
Faculty of Information Technologies, University „Dzemal Bijedic“ Mostar, Bosnia and Herzegovina 4
Radiology Department, Clinical center of Sarajevo, University Sarajevo, Bosnia and Herzegovina 5
CHC Lukavica, East Sarajevo, Bosnia and Herzegovina6

Corresponding author: Zora Vukobrat-Bijedic, MD, PhD. Gastroenterohepatology department, Clinical Center of Sarajevo, University Sarajevo, Bosnia and Herzegovina. E-mail: zoravukobratbijedic@gmail.com

ABSTRACT

Background: HCV infection is characterized by a tendency towards chronicity. Acute HCV infection progresses to chronic infection in 70% of cases. Hepatitis C virus infection can cause progressive liver injury and lead to fibrosis and eventually cirrhosis. The degree of histologic fibrosis is an important marker of the stage of the disease. One of current standard treatment for CHC infection is the combination of PEG-IFN α and ribavirin. Objectives: The aim of the study was to investigate the effect of the therapy with Peginterferon alfa-2a or alfa-2b plus Ribavirin on evolution of liver fibrosis in patients with chronic hepatitis C. Also, our aim was to examine whether there was a difference between the genders in the efficacy of these antiviral therapy. Our goal also was to determine effect of the therapy with Peginterferon alfa-2a or alfa-2b plus Ribavirin on evolution of liver steatosis in patients with chronic hepatitis C. Patients and Methods: A retrospective study was made of chronic hepatitis C patients who had been treated from 2005 to April 2014 at the Clinic of Gastroenterohepatology, Clinical Center University of Sarajevo. We reviewed 40 patient medical records to collect demographic, epidemiological and clinical information, as information on liver biopsies that was performed prior to the antiviral therapy and FibroScan® test that was performed after the antiviral therapy. For the processing of data SPSS (Statistical Package for the Social Sciences Program) for Windows, ver. 21.0 statistical software was used. Comparisons between qualitative and quantitative variables were performed using the Student t-test. Mann Whitney U test was used to compare differences in variables such as fibrosis stage and steatosis grade. A value of p<0.05 was considered as statistically significant. Results: After treatment, there was a statistically significant increase in the number of patients with no fibrosis (p<0.05). There was a statistically significant increase in the number of patients with cirrhosis (F4) (p>0.05). There was significantly higher decrease of fibrosis progression at the patients that were in an mild-to-moderate fibrosis (F1/F2/F3), patients that were in advanced stage of fibrosis (F4) at the time of the pre-treatment did not have a statistically significant fibrosis reduction. We found significant association in evolution of fibrosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2a (12,5) kD with ribavirin (p<0.05). We also found significant association in evolution of steatosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2a (12,5) kD with ribavirin (p<0.05). There was a statistically significant differences (p<0.05) between genders within fibrosis qualitative evolution. Conclusions: There were significant regression of fibrosis especially at the patients that were in an mild-to-moderate fibrosis (F1/F2/F3), patients that were in advanced stage of fibrosis (F4) at the time of the pre-treatment did not have a statistically significant fibrosis reduction after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin. Our results showed significant improvement in steatosis in patients infected with HCV after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin. Those results provides further evidence for direct involvement of HCV and antiviral therapy in the pathogenesis of hepatic steatosis. Female gender showed a higher degree of fibrosis reduction.

Key words: Antiviral Therapy, Regression.

1. BACKGROUND

The hepatitis C virus (HCV) is a major factor in the development of chronic liver disease worldwide. HCV infection is characterized by a tendency towards chronicity. Acute HCV infection progresses to chronic infection in 70% of cases. Chronic hepatitis C is a major health problem with an estimated prevalence of 1.6%–2% worldwide. It is estimated that in Europe, more than 9 million chronic carriers are progressing to the late complications of HCV with approximately 86,000 deaths per year (1, 2).

Because of their high genetic variability, HCV has the ability to avoid immune response of the host. This virus...
is not directly cytopathic and liver damage are mostly caused by immune-mediated mechanisms, predominantly T helper cell response (3). Hepatitis C virus infection can cause progressive liver injury and lead to fibrosis and eventually cirrhosis. The degree of histologic fibrosis is an important marker of the stage of the disease (3). Most of the complications related to chronic infection occurs in patients who have established cirrhosis (4-6). Treatments that could stop or diminish the progression of fibrosis would theoretically be beneficial (7).

One of the current standard treatment for CHC infection especially in the low income countries, is the combination of PEG-IFN α and ribavirin. The efficacy endpoint of hepatitis C treatment is the 'sustained virological response' (SVR), defined by the absence of detectable HCV RNA in serum, as assessed by an HCV RNA assay with a lower limit of detection of 1000 copies/ml or less, 6 months after the end of treatment (8).

The IFNs are a family of proteins that are naturally produced by the cells of the immune system which presents antiviral, anti proliferative and immunomodulatory activity (9). Its mechanism of biological action occurs through the activation of specific genes, influencing cell growth and division, as well as modulating some immune system activities. Therefore, IFN-α has an indirect antiviral effect on HCV (10). Commercially, IFN-α is produced by means of recombinant DNA techniques and is available in preparations of two distinct subtypes (IFN-α 2a or IFN-α 2b)(11). The only difference between IFN-α 2a and IFN-α 2b is in the amino acid present at position 23 of the protein: IFN-α 2a has a lysine at that position, whereas IFN-α 2b has an arginine (12). Pegylated IFNs (PEG-IFNs) are produced through the binding of an inert molecule of polyethylene glycol to the recombinant IFN-α, thus reducing the renal clearance, altering the metabolism and increasing the half-life of the IFN molecule, although maintaining all of its immunostimulatory characteristics (13). After the binding with its specific receptor (interferon-α/β receptor, IFNAR) on the surface of the target cells, IFN-α activates an intracellular signaling cascade, which takes the induction of IFN-stimulated genes (ISGs), encoding antiviral proteins such as 2′5′-oligoadenylate synthetase (2′5′OAS), protein kinase RNA, and Mx protein establishing a non-virus-specific antiviral state inside the cell (12). Ribavirin is a synthetic nucleoside which is structurally similar to guanosine (14). Ribavirin enters into the eucaryotic cells rapidly and, after it undergoes intracellular phosphorylation, shows virustatic activity against a broad spectrum of DNA and RNA viruses (14). The exact mechanism of the antiviral action of ribavirin has not yet been totally elucidated (15). However, some studies suggest the following possible mechanisms: direct inhibition of HCV replication, inhibition of the enzyme inosine monophosphate dehydrogenase of the host, induction of mutagenesis in the viral RNA, immunomodulation by the induction of a T helper 1 (Th1)-type immune response (15).

2. OBJECTIVES

The aim of the study was to analyze the effect of the therapy with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin on evolution of liver fibrosis in patients with chronic hepatitis C.

Also, our aim was to examine whether there was a difference between the genders in the efficacy of these antiviral therapy.

Our aim also was to determine effect of the therapy with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin on evolution of liver steatosis in patients with chronic hepatitis C.

3. PATIENTS AND METHODS

A retrospective study was made in a group of chronic hepatitis C patients treated from 2005 to April 2014 at the Clinic of Gastroenterohepatology, Clinical Center University of Sarajevo. We reviewed 40 patient medical records to collect demographic, epidemiological and clinical information, as information on liver biopsies and FibroScan® test.

The diagnosis of chronic hepatitis C was based on elevated transaminase activity in serum testing positive for anti-HCV antibodies (third-generation ELISA) and the presence of HCV RNA (PCR) in the serum, as well as histological evidence of chronic hepatitis. To determine the HCV genotype, Versant kit (Lipasa)® was used. The inclusion criteria were:

a) previous antiviral treatment for 24 or 48 weeks, depending on genotype, with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin using standardized doses and ways of administration;

b) a liver biopsy performed and reviewed by a pathologist, performed within six months prior to treatment;

c) examination with FibroScan® after treatment.

Patients associated with other diseases (acute, chronic or autoimmune either the liver or other organ systems) were excluded from the study.

Liver biopsies were analyzed always by the same pathologist from the Department of Pathology, Clinical Center University of Sarajevo applying the METAVIR fibrosis score. Steatosis was scored using the Brunt grading system in which steatosis is graded 0 to 3 based on percentage of hepatocytes involved.

3.1. Statistical analysis

For the processing of data SPSS (Statistical Package for the Social Sciences Program) for Windows, ver. 21.0 statistical software was used. Descriptive statistical analysis was used, and distributions of categorical variables were compared using Fisher tests. Continuous data were expressed as means, medians and standard deviation (SD). Comparisons between qualitative and quantitative variables were performed using the Student t-test. Mann Whitney U test was used to compare differences in variables such as fibrosis stage and steatosis grade. A value of p <0.05 was considered as statistically significant.

4. RESULTS

Forty patients met the inclusion criteria. Table 1 shows the main characteristics of the 40 patients included in this study.
Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

No. of patients 40
Age, years, Mean 51.65±10.66
Min 35
Max 75
Gender, No.(%)
Male 24 (60)
Female 16 (40)
Genotype HCV, No (%)
1a 20 (50)
1b 10 (25)
2 1 (2.5)
3 4 (10)
4 5 (12.5)
Median fibrosis stage 2* 0**
Median steatosis grade 0' 1**
Initial serum HCV RNA Median (millions IU/mL) 7.4

Table 1. Characteristics of the patients - pre-treatment "post-treatment"

Tables 2 and 3 summarizes the information about the evolution in fibrosis, after treatment with PEG-IFN α and ribavirin.

| METAVIR Fibrosis Stage | Pre-treatment, No. (%) |
|------------------------|------------------------|
| No fibrosis (F0)       | 4 (10)                 |
| Portal fibrosis (F1)   | 15 (37.5)              |
| Few septa (F2)         | 10 (25)                |
| Many septa (F3)        | 7 (17.5)               |
| Cirrhosis (F4)         | 4 (10)                 |
| FibroScarf/Fibrosis Stage | Post-treatment, No. (%) |
| No fibrosis           | 27 (67.5)              |
| F1                    | 10 (10)                |
| F2                    | 1 (2.5)                |
| F3                    | 4 (10)                 |
| F4                    | 4 (10)                 |

Table 2. Pre-treatment fibrosis stages

Table 3. Post-treatment fibrosis stages

After treatment, there was a statistically significant increase in the number of patients with no fibrosis (p<0.05), and a significant reduction in the number of patients with fibrosis grade (F1), (F2) and (F3) (p<0.05). There was no statistically significant reduction in the number of patients with cirrhosis (F4) (p> 0.05) (Tables 2 and 3). After the treatment, the most frequent were patients with no fibrosis (67.5%), a minimum frequent were patients with grade (F2) (2.5%), while patients with fibrosis grade (F1), grade (F3) and cirrhosis (F4) had the same frequency (10%) (Tables 2 and 3).

| Evolution | N % | p |
|-----------|-----|---|
| Non-progression (stabilization) | 10 25 | < 0.05 |
| Progression | 2 3 |
| Regression | 28 70 |

Table 4. Post-treatment fibrosis qualitative evolution.

Thirty-eight patients (95%) showed stabilization or regression of fibrosis (no progression) at the FibroScan® test performed after the treatment (Table 4). Before treatment, the vast majority of patients had evidence of fibrosis progression (fibrosis stage > 0) (Table 2). In contrast, after the treatment, most patients presented a tendency towards regression (Tables 3 and 4), therefore we found significant association in evolution of fibrosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin (p < 0.05) (Table 4).

| Evolution | N % | p |
|-----------|-----|---|
| Non-progression (stabilization) | 15 37.5 | < 0.05 |
| Progression | 24 60 |
| Regression | 1 2.5 |

Table 5. Post-treatment steatosis qualitative evolution.

Twenty-four patient (60%) showed progression of steatosis (Table 5) after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin. Most patients showed a tendency towards progression, therefore we found significant association in evolution of steatosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin (p < 0.05) (Table 5), with limitation of the data, since presence of steatosis was measured by two different methods.

We also found the statistically significant differences (p<0.05) between genders in fibrosis qualitative evolution (Table 6), female gender showed a higher degree of fibrosis reduction.

| Evolution | Male | Female | p |
|-----------|------|--------|---|
| Non-progression (stabilization) | 9 37.5 | 1 6.25 | < 0.05 |
| Regression | 14 58.3 | 14 87.5 |
| Progression | 1 4,16 | 1 6,25 |

Table 6. Fibrosis qualitative evolution according to gender

5. DISCUSSION

Regression of liver fibrosis has been a main topic of research and discussion in the community of liver experts for decades. Regression or reversibility of fibrosis has been perceived to be not much more than a myth. However, recent data have convincingly demonstrated
the occurrence of fibrosis regression in a wide spectrum of chronic liver diseases, including viral chronic hepatitis. In our study, the vast majority of patients had evidence of fibrosis before treatment (fibrosis stage > 0). In contrast, after treatment, most patients displayed a tendency towards regression, i.e. 38 patients showed stabilization or regression of fibrosis (no progression) at the FibroScan® test (Table 3). Therefore, we found significant association in evolution of fibrosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin (p=0.000, p<0.05) (Table 4). Similar results have been found in other studies (16, 17, 18,19) i.e. there is growing clinical evidence that fibrosis can regress and possibly even resolve in a number of liver diseases. It is difficult to believe from a clinical perspective that established cirrhosis may resolve to a pre-cirrhotic state. There are however, a number of studies reporting evidence of such reversal (20, 21, 22, 23). This evidence is predominantly based on changes in histological stage.

The observation of hepatic fibrosis regression in 28 patients is a very important piece of information, since spontaneous regression of hepatic fibrosis is not usually seen in patients without treatment. We speculate that the regression in fibrosis is due to an anti fibrogenic effect of interferon, regardless of its antiviral action. Poynard et al. demonstrated that hepatitis C is indeed a progressive fibrotic disease, which is the reason for its morbidity and mortality (24). Therefore, a therapeutic intervention to decrease or revert hepatic fibrosis progression will probably have a relevant clinical impact. On the other hand, the relevant fibrosis stabilization rates in patients with mild-to-moderate, as well as advanced fibrosis (10%), are probably due to the anti-inflammatory action of ribavirin, rebetol and interferon, with the possibility that the ribavirin and rebetol indirectly facilitated the interferon anti fibrogenic effect through its anti-inflammatory action.

In our study, steatosis was significantly increased after antiviral therapy (p<0.05). Our results are in agreement with the results of previous studies (25, 26) that have determined significant progression in steatosis in patients infected with HCV. This provides further evidence for direct involvement of HCV and antiviral therapy in the pathogenesis of hepatic steatosis. Those results should be taken in to the consideration, since the presence of liver steatosis was analyzed by two different methods. Female gender showed a higher degree of fibrosis reduction.

**CONFLICT OF INTEREST: NONE DECLARED.**

**REFERENCES**

1. Méndez-Sánchez N, Villa AR, Zamora-Valdés D. et al. Worldwide mortality from cirrhosis. Annals of Hepatology. 2007; 6(3): 194-195.
2. Esteban JI, Saulea S, QuejF. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008 Jan; 48(1): 148-162.
3. Rosenberg W. Mechanisms of immune escape in viral hepatitis. Gut. 1999; 44: 759-764.
4. Poynard T, Bedossa P, Opolon P. For the OBSVIRC, METAIVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997; 349: 825-832.
5. El-Serag HB, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 34: 745-750.
6. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology. 1999; 29: 1596-1601.
7. Alter MJ, Kruuszon-Moran D, Nainan OV. et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341: 556-562.
8. Sobesky R, Mathurin P, Charlotte F. et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology. 1999; 116: 378-386.
9. Manns MP, McHutchison JG, Gordon SC. et al. PEG-Interferon alfa-2b plus ribavirin in treatment of chronic hepatitis C: a dynamic view. Gastroenterology. 1999; 116: 378-386.
10. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005; 436(7053): 967-972.
11. Souvignet C, Lejeune O, Trep C. Interferon-based treatment of chronic hepatitis C. Biochimie. 2007; 89(6-7): 894-898.
12. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004; 20(8): 825-830.
13. Pestka S. The human interferon alpha species and receptors. Biopolymers. 2000; 55(4): 254-287.
14. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon α2b. Annals of Hepatology. 2007; 6(3): 194-195.
alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001; 33(2): 433-438.
15. Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol. 2006; 16(1): 37-48.
16. Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res. 2005; 107(2): 165-171.
17. Abe S, Tabaru A, Ono M. et al. High-dose interferon-α therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C. Hepatology Research. 2003; 25: 22-31.
18. Pol S, Carnot F, Nalpas B. et al. Reversibility of hepatitis C virus-related cirrhosis. Human Pathol. 2004; 35(1): 107-112.
19. Prado K, Patzina R, Bergamaschi D, Focaccia R. Histological Response Study of Chronic Viral Hepatitis C Patients Treated With Interferon Alone or Combined With Ribavirin. BJID. 2008; 12(5): 362-367.
20. Mallet V, Gilgenkrantz H, Serpaggi J. et al. Cirrhosis Regression in Chronic Hepatitis C: An Old Tale With a New Ending. Gastroenterology. 2009; 136(4): 1447-1449.
21. Germani G, Hytiroglou P, Fotiadu A. et al. Assessment of Fibrosis and Cirrhosis in Liver Biopsies. Semin Liver Dis. 2011; 31(1): 82-90.
22. Palumbo E. Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection. Ther Adv Chronic Dis. 2011; 2(1): 39-45.
23. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012; 56(5): 1171-1180.
24. Poynard T, Moussalli J, Munteanu M. et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. Journal of Hepatology. 2013; 59(4): 675-683.
25. Vukobrat-Bijedić Z, Mededovic A, Redzepovic A, Gogov B. Use of Serum Levels of Proinflammatory Cytokine IL-1α in Chronic Hepatitis B. Med Arh. 2014 Feb; 68(2): 94-97. doi: 10.5455/medarh.2014.68.94-97.
26. Castèra L, Hézode C, Roudot-Thoraval F. et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004; 53(3): 420-424.
27. Hung CH, Kuo FY, Wang JH. et al. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther. 2006; 11(4): 483-489.